Literature DB >> 7226032

A statistical evaluation of baseline and follow-up carcinoembryonic antigen in patients with resectable colorectal carcinoma.

P T Lavin, J Day, E D Holyoke, A Mittelman, T M Chu.   

Abstract

A long-term CEA follow-up was evaluated statistically for a series of 74 patients with primary colorectal carcinoma who underwent resections for cure. Thirty-three recurrences and 29 deaths were reported among this population after a median follow-up interval of 55 months. Preoperative CEA levels correlated with the Dukes' classification. However, the preoperative level adds significant information to Dukes' classification in the prediction of recurrence. Postoperative CEA assays taken later in the clinical evaluation process carry the most prognostic information for subsequent recurrence. Using matched-pairs techniques, the authors noted that CEA often rose in anticipation of recurrence, sometimes as early as one year before recurrence. The following four follow-up CEA events were evaluated: 1) three consecutive rising CEA's 2) CEA rises 5.0 ng/ml; 3) CEA exceeds 5.0 ng/ml; 4) CEA exceeds 5.0 ng/ml two consecutive times. The follow-up CEA events examined were characterized by false positive rates ranging from 17% to 66% and true positive rates ranging from 43% to 56% in the prediction of recurrence. From follow-up CEA evaluations, further clinical investigation appeared most warranted when CEA exceeds 5.0 ng/ml at two consecutive follow-up evaluations, but the chances of finding any subsequent recurrent disease was near 50%. Among patients experiencing recurrences, although forewarned by CEA elevations, there was no subsequent time when patients were most likely to have recurrence of disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7226032     DOI: 10.1002/1097-0142(19810215)47:4<823::aid-cncr2820470433>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma.

Authors:  J Boey; H C Cheung; C K Lai; J Wong
Journal:  World J Surg       Date:  1984-06       Impact factor: 3.352

2.  Hepatic resection for metastatic cancer.

Authors:  W J Kortz; W C Meyers; J B Hanks; B D Schirmer; R S Jones
Journal:  Ann Surg       Date:  1984-02       Impact factor: 12.969

3.  Plasma carcinoembryonic antigen concentrations and immunohistochemical patterns of epithelial marker antigens in patients with large bowel carcinoma.

Authors:  T Rognum; K Elgjo; P Brandtzaeg; H Orjasaeter; A Bergan
Journal:  J Clin Pathol       Date:  1982-09       Impact factor: 3.411

Review 4.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

5.  Large-bowel carcinomas with different ploidy, related to secretory component, IgA, and CEA in epithelium and plasma.

Authors:  T O Rognum; E Thorud; K Elgjo; P Brandtzaeg; H Orjasaeter; K Nygaard
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.